An experimental drug, LX211 (LUVENIQâ„¢; oral voclosporin), may become the first approved oral treatment capable of modifying the course of uveitis, a group of serious eye conditions inevitably associated with either severe vision loss or substantial morbidity from steroid use.

Lux Biosciences has reported that the FDA has granted Fast Track designation for LX201, a silicone matrix ocular implant that steadily releases therapeutic doses of cyclosporine A locally to the eye, to prevent corneal transplant rejection.

Serious eye diseases like uveitis, macular degeneration and dry eye syndrome threaten the eyesight and lower the quality of life for many thousands of people each year.

An EMEA committee has adopted a positive opinion on orphan medicinal product designation for Lux Biosciences' investigational therapeutic for the treatment of chronic, non-infectious uveitis.

Isotechnika has said that its lead immunosuppressive drug ISA247 for eye disease is positioned to enter phase II/ III trials by its partner Lux Biosciences after clearance of its investigational new drug application by the FDA.